Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Kamburova, Elena G ^a   Koenen, Hans J P M ^a   Van Den Hoogen, Martijn W F ^a   Baas, Marije C ^a   Joosten, Irma ^a   Hilbrands, Luuk B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD19 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; MALE; MEMORY CELL; ORGAN DONOR; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; CYTOLOGY; DRUG COMBINATION; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; KIDNEY; LYMPHOCYTE DEPLETION; MIDDLE AGED; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHENOTYPE; RENAL INSUFFICIENCY, CHRONIC; STEROIDS; TACROLIMUS;

EID: 84911882765     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112658     Document Type: Article

References (41)

1. Chapman JR, O'Connell PJ, Nankivell BJ (2005) Chronic renal allograft dysfunction. J Am Soc Nephrol 16: 3015-3026.
2. Safinia N, Afzali B, Atalar K, Lombardi G, Lechler RI (2010) T-cell alloimmunity and chronic allograft dysfunction. Kidney International 78 Suppl 119: S2-12.
3. Kahan BD (2003) Individuality: The barrier to optimal immunosuppression. Nat Rev Immunol 3: 831-838.
4. Wood KJ, Bushell A, Hester J (2012) Regulatory immune cells in transplantation. Nat Rev Immunol 12: 417-430.
5. Kreijveld E, Koenen HJ, van Cranenbroek B, van Rijssen E, Joosten I, et al. (2008) Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 3: E2711.
6. Zarkhin V, Chalasani G, Sarwal MM (2010) The yin and yang of B cells in graft rejection and tolerance. TransplantRev(Orlando) 24: 67-78.
7. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS (2005) Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 5: 2248-2252.
8. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, et al. (2008) Characterization of intra-graft B cells during renal allograft rejection. Kidney International 74: 664-673.
9. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD (2012) Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 12: 1618-1623.
10. Jordan SC, Kahwaji J, Toyoda M, Vo A (2011) B-cell immunotherapeutics: Emerging roles in solid organ transplantation. Curr Opin Organ Transplant 16: 416-424.
11. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, et al. (2008) Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response. Annals of the Rheumatic Diseases 67: 917-925.
12. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, et al. (2010) Abnormal Bcell cytokine responses a trigger of T-cell-mediated disease in MS? Annals of Neurology 67: 452-461.
13. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, et al. (2010) Changes in B- And T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Archives of Neurology 67: 707-714.
14. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, et al. (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 8: R83.
15. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 22: 745-763.
16. Lechler RI, Garden OA, Turka LA (2003) The complementary roles of deletion and regulation in transplantation tolerance. NatRevImmunol 3: 147-158.
17. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM (2001) Bm1- Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. JImmunol 167: 3610-3618.
18. van de Berg PJ, Hoevenaars EC, Yong SL, van Donselaar-van der Pant KA, van Tellingen A, et al. (2012) Circulating lymphocyte subsets in different clinical situations after renal transplantation. Immunology 136: 198-207.
19. Koenen HJ, Michielsen EC, Verstappen J, Fasse E, Joosten I (2003) Superior Tcell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation 75: 1581-1590.
20. Sallusto F, Lanzavecchia A, Mackay CR (1998) Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunology Today 19: 568-574.
21. Matz M, Beyer J, Wunsch D, Mashreghi MF, Seiler M, et al. (2006) Early posttransplant urinary IP-10 expression after kidney transplantation is predictive of short- And long-Term graft function. Kidney Int 69: 1683-1690.
22. Demmers MW, Baan CC, van Beelen E, Ijzermans JN, Weimar W, et al. (2013) Differential effects of activated human renal epithelial cells on T-cell migration. PLoS One 8: E64916.
23. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, et al. (2008) Effects of immunosuppressive drugs on purified human B cells: Evidence supporting the use of MMF and rapamycin. Transplantation 86: 1292-1300.
24. Eickenberg S, Mickholz E, Jung E, Nofer JR, Pavenstadt HJ, et al. (2012) Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther 14: R110.
25. Hanson RG, Peters MG, Hoofnagle JH (1986) Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 6: 173-179.
26. Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS (1985) Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest 75: 754-761.
27. Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131: 959-971.
28. de lTI, Moura RA, Leandro MJ, Edwards J, Cambridge G (2010) B-cellactivating factor receptor expression on naive and memory B cells: Relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Annals of the Rheumatic Diseases 69: 2181-2188.
29. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, et al. (2006) Differential effects on BAFF and APRIL levels in rituximab-Treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8: R167.
30. Zarkhin V, Li L, Sarwal MM (2009) BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 88: 1229-1230.
31. Bloom D, Chang Z, Pauly K, Kwun J, Fechner J, et al. (2009) BAFF is increased in renal transplant patients following treatment with alemtuzumab. AmJTransplant 9: 1835-1845.
32. Lehnhardt A, Dunst F, van Husen M, Loos S, Oh J, et al. (2012) Elevated serum levels of B-cell activating factor in pediatric renal transplant patients. Pediatr Nephrol 27: 1389-1395.
33. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, et al. (2009) B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A 106: 13945-13950.
34. Duddy ME, Alter A, Bar-Or A (2004) Distinct profiles of human B cell effector cytokines: A role in immune regulation? JImmunol 172: 3422-3427.
35. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, et al. (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. NatImmunol 1: 475-482.
36. Janeway CA, Jr., Ron J, Katz ME (1987) The B cell is the initiating antigenpresenting cell in peripheral lymph nodes. JImmunol 138: 1051-1055.
37. Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I (2012) In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 12: 341-350.
38. Smeekens SP, van den Hoogen MW, Kamburova EG, van de Veerdonk FL, Joosten I, et al. (2013) The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production. Transpl Immunol 28: 183-188.
39. Kamburova EG, Koenen HJ, Borgman KJ, ten Berge IJ, Joosten I, et al. (2013) A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 13: 1503-1511.
40. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, et al. (2011) Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. Journal of Rheumatology 38: 633-641.
41. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, et al. (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112: 1147-1150.